India, Sept. 15 -- Oruka Therapeutics, Inc. (ORKA) is advancing its late-stage psoriasis strategy, with 28+ week follow-up data from the Phase 2a EVERLAST-A trial of ORKA-001 expected at the end of the third quarter of 2026.
ORKA-001 is a novel half-life extended IL-23p19 monoclonal antibody being developed for chronic inflammatory skin diseases, with the potential to support once- to twice-yearly dosing.
What's Driving The Stock?
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....